
The battle for the short bowel syndrome market is getting tougher.
The Novo Ventures-backed spinout company Vectivbio will soon enter the US stock exchange hoping to land USD 127.5m for further developing the firm's drug hope apraglutide. Following solid results in a phase II study for short bowel syndrome, drug was recently tested on the first patient in the crucial phase III trial, according to a press announcement from the Swiss company, which was founded in 2020 with backing from a series of life science venture funds.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app